Organisation paid for research Program year 2025 Source: CMS Open Payments

Research By Design LLC

Neither a doctor nor a teaching hospital

Research payments

$2,935,416

345 payments

Through program year 2025, Research By Design LLC is reported as receiving $2,935,416 in research payments, across 345 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$419,166	109
2024	Research	$509,753	13
2023	Research	$138,848	13
2022	Research	$462,203	23
2021	Research	$700,166	67
2020	Research	$422,910	33
2019	Research	$282,370	87

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $1,254,401 35 payments
Bayer HealthCare Pharmaceuticals Inc. $705,933 48 payments
GlaxoSmithKline, LLC. $359,407 50 payments
Eli Lilly and Company $310,639 1 payment
Dendreon Pharmaceuticals LLC $108,480 20 payments
Pfizer Inc. $75,661 16 payments
Gilead Sciences, Inc. $29,934 13 payments
Genzyme Corporation $25,475 1 payment
OPKO Pharmaceuticals, LLC $23,749 4 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $17,873 60 payments

Studies the money was for Research payments · program years 2019–2025

BI 685509 Dose finding PoCC in DKD $478,334 5 payments
An observer-blind multi-center placebo-controlled parallel group study to assess the safety and tolerability and to characterize the pharmacokinetics and the pharmacodynamics of different doses of BAY 1213790 in patients with end-stage renal disease undergoing hemodialysis $361,781 25 payments
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating Ly3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy $310,639 1 payment
BI 685509 Dose finding/PoCC in DKD $279,909 5 payments
Osocimab in ESRD Phase 2b study $248,834 14 payments
A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $210,274 31 payments
BI 685509 Dose finding PoCC in Non Diabetic CKD $201,151 5 payments
BI 685509 Dose finding/PoCC in Non-Diabetic CKD $145,154 5 payments
BAY1213790 PK/PD in ESRD patients on dialysis $95,318 9 payments
MRD for BI 685509 in DN Patients $79,126 58 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.